← Back to Search

Ophthalmic Solution

QLS-101ophthalmic solution 2% for Glaucoma

Phase 2
Waitlist Available
Research Sponsored by Qlaris Bio, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 56 days, including a 14-day washout
Awards & highlights

Study Summary

This study is evaluating whether a drug called QLS-101 can be safely used to treat people with Sturge Weber Syndrome (SWS)-related glaucoma.

Eligible Conditions
  • Glaucoma
  • Ocular Hypertension
  • Developmental Glaucoma
  • Sturge-Weber Syndrome

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~56 days, including a 14-day washout
This trial's timeline: 3 weeks for screening, Varies for treatment, and 56 days, including a 14-day washout for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Dilated fundus exam
Enhance depth imaging optical coherence tomography (EDI-OCT)
Ocular adverse events (AEs)
+2 more
Secondary outcome measures
Ocular hypotensive efficacy

Trial Design

2Treatment groups
Experimental Treatment
Group I: 2% QLS-101Experimental Treatment1 Intervention
dosed once a day for 14 as either first or second dosing period per randomization
Group II: 1% QLS-101Experimental Treatment1 Intervention
dosed once a day for 14 days as either first or second dosing period per randomization
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
QLS-101ophthalmic solution 1%
2021
Completed Phase 2
~10
QLS-101ophthalmic solution 2%
2021
Completed Phase 2
~10

Find a Location

Who is running the clinical trial?

Qlaris Bio, Inc.Lead Sponsor
6 Previous Clinical Trials
344 Total Patients Enrolled
6 Trials studying Glaucoma
344 Patients Enrolled for Glaucoma
B. Wirostko, M.D.Study DirectorQlaris Bio, Inc.
1 Previous Clinical Trials
30 Total Patients Enrolled
1 Trials studying Glaucoma
30 Patients Enrolled for Glaucoma

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
A Study to Determine the Safety and Tolerability of 2 Concentrations of QLS-101
2021. "A Study to Determine the Safety and Tolerability of 2 Concentrations of QLS-101". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04947124.
~1 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top